CAR-T cell therapies targeting CD123, CD33 and CLL-1 have shown preliminary efficacy and safety in clinical trials for r/r AML, though the low response rates for CAR-T cells in r/r AML indicate there are still challenges to overcome [10–13]. This evidence concerns the gene CD33 and acute myeloid leukemia.